Shire

Shire may return cash to thwart takeover, Daily Mail reports

Shire may return cash to thwart takeover, Daily Mail reports

Yahoo/Fly on the Wall

Shire cuts sales forecast as some drugs miss Q1 targets

Shire cuts sales forecast as some drugs miss Q1 targets

Reuters

Why GlaxoSmithKline Beats AstraZeneca and Shire

Why GlaxoSmithKline Beats AstraZeneca and Shire

Motley Fool

Why GlaxoSmithKline Beats AstraZeneca and Shire

Why GlaxoSmithKline Beats AstraZeneca and Shire

Motley Fool

ViroPharma: Generic Concerns Overblown, Pipeline Will Bring Revenue Diversity

ViroPharma: Generic Concerns Overblown, Pipeline Will Bring Revenue Diversity

Seeking Alpha

Shire to Buy Eye-Drug Maker SARcode for $160 Million

Shire to Buy Eye-Drug Maker SARcode for $160 Million

Bloomberg

Shire buys Premacure and its infant eye drug

Shire buys Premacure and its infant eye drug

Pharma Times, UK

Bristol-Myers might just make a big deal, WSJ says

Bristol-Myers might just make a big deal, WSJ says

Fierce Pharma

Teva Announces FDA Approval of Generic Adderall XR®

Teva Announces FDA Approval of Generic Adderall XR®

Yahoo

Shire to Forest on Deal List for AstraZeneca: Real M&A

Shire to Forest on Deal List for AstraZeneca: Real M&A

Bloomberg